Loading...
XSTO
RAY B
Market cap1.09bUSD
May 30, Last price  
305.50SEK
1D
0.83%
1Q
21.96%
Jan 2017
65.58%
Name

RaySearch Laboratories AB (publ)

Chart & Performance

D1W1MN
P/E
51.46
P/S
8.79
EPS
5.94
Div Yield, %
0.43%
Shrs. gr., 5y
—
Rev. gr., 5y
9.96%
Revenues
1.19b
+16.62%
69,855,00068,976,00064,705,00062,690,00083,687,000117,728,000126,103,000182,087,000204,470,000285,217,000397,600,000531,468,000585,086,000627,219,000741,584,000651,612,000641,673,000843,648,0001,022,159,0001,192,029,000
Net income
204m
+149.49%
29,142,00036,219,00019,779,00018,223,00030,146,00028,895,00017,007,00019,863,000-20,841,00059,832,00070,209,000151,408,000117,627,00078,523,00050,411,000-9,080,000-47,315,00023,778,00081,572,000203,513,000
CFO
485m
+6.43%
41,393,00030,093,00037,862,00026,045,00049,207,00062,785,00033,852,00087,451,00031,282,00050,273,000111,426,000120,848,000147,481,000178,472,000320,145,000331,508,000238,162,000356,777,000455,931,000485,230,000
Dividend
May 23, 20253 SEK/sh
Earnings
Aug 14, 2025

Profile

RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities. In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.
URL
https://www.raysearchlabs.com/
IPO date
May 29, 1990
Employees
375
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,192,029
16.62%
1,022,159
21.16%
843,648
31.48%
Cost of revenue
945,046
902,323
814,903
Unusual Expense (Income)
NOPBT
246,983
119,836
28,745
NOPBT Margin
20.72%
11.72%
3.41%
Operating Taxes
59,352
28,516
8,597
Tax Rate
24.03%
23.80%
29.91%
NOPAT
187,631
91,320
20,148
Net income
203,513
149.49%
81,572
243.06%
23,778
-150.25%
Dividends
(68,566)
Dividend yield
0.93%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
77,079
97,381
58,307
Long-term debt
866,789
961,335
1,052,464
Deferred revenue
Other long-term liabilities
879
878
743
Net debt
481,128
691,415
895,806
Cash flow
Cash from operating activities
485,230
455,931
356,777
CAPEX
(13,261)
(24,295)
(231,501)
Cash from investing activities
(217,543)
(209,330)
(231,501)
Cash from financing activities
(159,778)
(56,350)
(78,492)
FCF
251,384
149,974
111,830
Balance
Cash
462,740
343,681
160,268
Long term investments
23,620
54,697
Excess cash
403,139
316,193
172,783
Stockholders' equity
733,257
657,551
Invested Capital
1,349,520
949,275
1,035,522
ROIC
16.32%
9.20%
1.86%
ROCE
16.87%
8.72%
2.19%
EV
Common stock shares outstanding
34,283
34,283
34,283
Price
216.00
139.20%
90.30
32.79%
68.00
20.35%
Market cap
7,405,153
139.21%
3,095,734
32.79%
2,331,229
20.35%
EV
7,886,281
3,787,149
3,229,405
EBITDA
246,983
405,990
325,745
EV/EBITDA
31.93
9.33
9.91
Interest
9,687
11,478
Interest/NOPBT
8.08%
39.93%